Villedieu M - Search Results

1

MicroRNA-125b upregulation confers aromatase inhibitor resistance and is a novel marker of poor prognosis in breast cancer.

Vilquin P, Donini CF, Villedieu M, Grisard E, Corbo L, Bachelot T, Vendrell JA, Cohen PA. Vilquin P, et al. Among authors: villedieu m. Breast Cancer Res. 2015 Jan 30;17(1):13. doi: 10.1186/s13058-015-0515-1. Breast Cancer Res. 2015. PMID: 25633049 Free PMC article.

2

ZNF217 confers resistance to the pro-apoptotic signals of paclitaxel and aberrant expression of Aurora-A in breast cancer cells.

Thollet A, Vendrell JA, Payen L, Ghayad SE, Ben Larbi S, Grisard E, Collins C, Villedieu M, Cohen PA. Thollet A, et al. Among authors: villedieu m. Mol Cancer. 2010 Nov 8;9:291. doi: 10.1186/1476-4598-9-291. Mol Cancer. 2010. PMID: 21059223 Free PMC article.

3

Molecular characterization of anastrozole resistance in breast cancer: pivotal role of the Akt/mTOR pathway in the emergence of de novo or acquired resistance and importance of combining the allosteric Akt inhibitor MK-2206 with an aromatase inhibitor.

Vilquin P, Villedieu M, Grisard E, Ben Larbi S, Ghayad SE, Heudel PE, Bachelot T, Corbo L, Treilleux I, Vendrell JA, Cohen PA. Vilquin P, et al. Among authors: villedieu m. Int J Cancer. 2013 Oct 1;133(7):1589-602. doi: 10.1002/ijc.28182. Epub 2013 May 2. Int J Cancer. 2013. PMID: 23553037

4

PI3K/mTOR dual inhibitor NVP-BEZ235 decreases Mcl-1 expression and sensitizes ovarian carcinoma cells to Bcl-xL-targeting strategies, provided that Bim expression is induced.

Jebahi A, Villedieu M, Pétigny-Lechartier C, Brotin E, Louis MH, Abeilard E, Giffard F, Guercio M, Briand M, Gauduchon P, Lheureux S, Poulain L. Jebahi A, et al. Among authors: villedieu m. Cancer Lett. 2014 Jun 28;348(1-2):38-49. doi: 10.1016/j.canlet.2014.03.001. Epub 2014 Mar 18. Cancer Lett. 2014. PMID: 24650799 Free article.

5

Bcl-XL and MCL-1 constitute pertinent targets in ovarian carcinoma and their concomitant inhibition is sufficient to induce apoptosis.

Brotin E, Meryet-Figuière M, Simonin K, Duval RE, Villedieu M, Leroy-Dudal J, Saison-Behmoaras E, Gauduchon P, Denoyelle C, Poulain L. Brotin E, et al. Among authors: villedieu m. Int J Cancer. 2010 Feb 15;126(4):885-95. doi: 10.1002/ijc.24787. Int J Cancer. 2010. PMID: 19634140

6

The mTORC1/2 Inhibitor AZD8055 Strengthens the Efficiency of the MEK Inhibitor Trametinib to Reduce the Mcl-1/[Bim and Puma] ratio and to Sensitize Ovarian Carcinoma Cells to ABT-737.

Pétigny-Lechartier C, Duboc C, Jebahi A, Louis MH, Abeilard E, Denoyelle C, Gauduchon P, Poulain L, Villedieu M. Pétigny-Lechartier C, et al. Among authors: villedieu m. Mol Cancer Ther. 2017 Jan;16(1):102-115. doi: 10.1158/1535-7163.MCT-16-0342. Epub 2016 Dec 15. Mol Cancer Ther. 2017. PMID: 27980105

7

Acquisition of chemoresistance following discontinuous exposures to cisplatin is associated in ovarian carcinoma cells with progressive alteration of FAK, ERK and p38 activation in response to treatment.

Villedieu M, Deslandes E, Duval M, Héron JF, Gauduchon P, Poulain L. Villedieu M, et al. Gynecol Oncol. 2006 Jun;101(3):507-19. doi: 10.1016/j.ygyno.2005.11.017. Epub 2006 Jan 4. Gynecol Oncol. 2006. PMID: 16387351

8

Effect of 2-deoxy-D-glucose on various malignant cell lines in vitro.

Zhang XD, Deslandes E, Villedieu M, Poulain L, Duval M, Gauduchon P, Schwartz L, Icard P. Zhang XD, et al. Among authors: villedieu m. Anticancer Res. 2006 Sep-Oct;26(5A):3561-6. Anticancer Res. 2006. PMID: 17094483 Free article.

9

Absence of Bcl-xL down-regulation in response to cisplatin is associated with chemoresistance in ovarian carcinoma cells.

Villedieu M, Louis MH, Dutoit S, Brotin E, Lincet H, Duigou F, Staedel C, Gauduchon P, Poulain L. Villedieu M, et al. Gynecol Oncol. 2007 Apr;105(1):31-44. doi: 10.1016/j.ygyno.2006.12.011. Epub 2007 Feb 1. Gynecol Oncol. 2007. PMID: 17275076

10

Anticancer and chemosensitizing effects of 2,3-DCPE in ovarian carcinoma cell lines: link with ERK activation and modulation of p21WAF1/CIP1, Bcl-2 and Bcl-xL expression.

Villedieu M, Briand M, Duval M, Héron JF, Gauduchon P, Poulain L. Villedieu M, et al. Gynecol Oncol. 2007 May;105(2):373-84. doi: 10.1016/j.ygyno.2006.12.019. Epub 2007 Feb 5. Gynecol Oncol. 2007. PMID: 17276501

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

15 results

Search Page

Filters